Bank of New York Mellon
ANTH

Bank of New York Mellon’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Bank of New York Mellon’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-16,912
Closed -$5K – 4378
2018
Q1 		$5K Buy
16,912
+2,503
+17% +$3.74K ﹤0.01% 4305
2017
Q4 		$24K Sell
14,409
-5,246
-27% -$9.03K ﹤0.01% 4293
2017
Q3 		$28K Buy
19,655
+5,246
+36% +$7.45K ﹤0.01% 4187
2017
Q2 		$23K Sell
14,409
-12,622
-47% -$28.3K ﹤0.01% 4222
2017
Q1 		$92K Buy
27,031
+2,120
+9% +$10K ﹤0.01% 4046
2016
Q4 		$129K Sell
24,911
-2,940
-11% -$50.9K ﹤0.01% 3980
2016
Q3 		$702K Sell
27,851
-995
-3% -$25.1K ﹤0.01% 3367
2016
Q2 		$714K Buy
28,846
+81
+0.3% +$2.29K ﹤0.01% 3356
2016
Q1 		$833K Buy
28,765
+4,048
+16% +$110K ﹤0.01% 3174
2015
Q4 		$918K Buy
24,717
+3,141
+15% +$139K ﹤0.01% 3223
2015
Q3 		$1.05M Sell
21,576
-727
-3% -$50.8K ﹤0.01% 3158
2015
Q2 		$1.54M Buy
22,303
+18,360
+466% +$850K ﹤0.01% 3080
2015
Q1 		$141K Buy
+3,943
New +$117K ﹤0.01% 3979

Other funds holding ANTH

WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Bank of New York Mellon's ANTH Position: Q2 2018 in Review

Bank of New York Mellon sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q2 2018, closing a stake of 16,912 shares — an estimated $5K sold.

Bank of New York Mellon first reported a position in ANTH in Q1 2015 and held it in 13 quarters. The position peaked at $1.54M in Q2 2015. 5 funds tracked by Wall St. Rank hold ANTH as of Q2 2018.

  • Bank of New York Mellon reported no remaining Anthera Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • Bank of New York Mellon sold 16,912 Anthera Pharmaceuticals, Inc. shares in Q2 2018, an estimated $5K.
  • Bank of New York Mellon first reported a position in Anthera Pharmaceuticals, Inc. in Q1 2015 and held it in 13 quarters.
  • Bank of New York Mellon's Anthera Pharmaceuticals, Inc. position peaked at $1.54M in Q2 2015.
  • 5 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q2 2018.

Based on Bank of New York Mellon's 13F filing for Q2 2018, filed 6 Aug 2018.